US EditionPublished • loading... • Updated
Merck & Co., Inc. and Eisai announce Phase 3 trial results for WELIREG plus LENVIMA in advanced renal cell carcinoma
Summary by Express Pharma
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Merck & Co., Inc. and Eisai announce Phase 3 trial results for WELIREG plus LENVIMA in advanced renal cell carcinoma
Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside the United States and Canada), and Eisai announced results from the Phase 3 LITESPARK-011 trial evaluating a dual oral regimen of WELIREG (belzutifan) and LENVIMA (lenvatinib) in patients with advanced renal cell carcinoma (RCC) whose disease progressed on or after anti-PD-1/L1 therapy. The trial met one of its primary endpoints of progression-free survival (PFS). At a pre-specified interi…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
